Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: therapeutic agents - Celltech Group/Medarex/Genmab

Drug Profile

Research programme: therapeutic agents - Celltech Group/Medarex/Genmab

Alternative Names: Breast cancer research programme - Celltech Group/Medarex; HuMax-Cancer; MDX 067; MDX-OGS 001; OGS-MDX 067; Research programme: breast cancer - Celltech Group/Medarex

Latest Information Update: 03 May 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab; Medarex; UCB
  • Developer UCB
  • Class Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Heparanase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 03 May 2007 Discontinued - Preclinical for Breast cancer in England (unspecified route)
  • 08 Dec 2003 The integration of Oxford GlycoSciences into Celltech Group has been completed
  • 12 Aug 2003 Oxford GlycoSciences has been acquired by Celltech Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top